Hans Lehrach is a prominent figure in drug discovery and genetics research. He is the Director and Scientific Member at the Max Planck Institute for Molecular Genetics in Germany, with a focus on genetics, genomics, and systems biology. Throughout his career, Lehrach has been involved in several groundbreaking genome sequencing projects, including the human, rat, and Schizosaccharomyces Pombe genomes. He is known for his key work on technologies such as protein microarrays, protein interactome analysis, yeast artificial chromosomes, and RNAseq. In recent years, his research has been dedicated to developing personalized medicine using "virtual patient" models based on deep -omics analysis. Additionally, Lehrach has co-founded several successful biotechnology companies, including Sequana Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech, Atlas Biolabs, Alacris Theranostics, and the Dahlem Centre for Genome Research and Medical Systems Biology gGmbH (DCGMS). His significant contributions have been recognized with awards such as the Ján Jessenius SAS Medal of Honour and the Karl Heinz Beckurts Award.